李永刚江苏省淮安市涟水县人民医院肾内科，江苏淮安　223499

舒洛地特联合缬沙坦治疗原发性肾小球肾炎的临床疗效

李永刚
江苏省淮安市涟水县人民医院肾内科，江苏淮安223499

目的探讨舒洛地特联合缬沙坦治疗原发性肾小球肾炎的疗效。方法选取2013年1月—2015年8月该院治疗的62例原发性慢性肾小球肾炎患者，随机分为观察组和对照组，各31例。观察组用舒洛地特联合缬沙坦治疗，对照组单用缬沙坦治疗，疗程结束后比较两组疗效。结果观察组患者总有效率90.3%明显高于对照组70.9%差异有统计学意义（P＜0.05）。两组治疗后SBP、TG、TC、PT、APTT比较差异无统计学意义；24 h尿蛋白、血浆纤维蛋白原以及胱抑素C水平均较治疗前下降，但观察组下降更为明显，差异有统计学意义（P＜0.05）。结论舒洛地特联合缬沙坦治疗原发性肾小球肾炎疗效显著，安全性高，值得推广。

舒洛地特；缬沙坦；原发性肾小球肾炎

［Abstract］Objective To investigate the curative effect of sulodexide combined with valsartan in the treatment of primary glomerulonephritis.Methods 62 cases of primary chronic glomerulonephritis in our hospital from January 2013 to August 2015 were randomly divided into the observation group and control group with each group of 31 cases.The observation group was treated with sulodexide combined with valsartan，and the control group was only treated with valsartan.The clinical effect of two groups were compared after treatment.Results The total effective rate of observation group （90.3%）was significantly higher than 70.9%of control group（P＜0.05）.The differences were not significant in the levels of SBP，TG，TC，PT，APTT between the two groups.The levels of urinary protein in 24 hours，plasma fibrinogen and cystatin C of patients in the two groups after treatment decreased，but the observation group decreased more significantly（P＜0.05）.Conclusion Sulodexide combined with valsartan in the treatment of primary glomerulonephritis has obvious effect，high safety，and is worthy of promotion.

［Key words］Sulodexide；Valsartan；Primary glomerulonephritis

原发性慢性肾小球肾炎是由各种病因引起的双侧肾小球弥漫性或局灶性炎症性或非炎症性改变。该病病理类型多样化，病情迁延，有不同程度的肾功能减退，最终可发展成终末期肾脏病［1-2］。该研究对2013 年1月—2015年8月该院治疗的原发性慢性肾小球肾炎患者应用舒洛地特联合缬沙坦治疗，效果较好，现报道如下。

1　资料与方法

1.1一般资料

选取2013年1月—2015年8月该院治疗的62例原发性慢性肾小球肾炎患者，符合原发性慢性肾小球肾炎诊断标准［3］，尿蛋白定量＜3.59的IgA肾病患者，eGFR＞90 mL/（min·1.73 m2）。其中男38例，女24例，年龄37～62岁，平均（44.5±7.3）岁；病程5～12年，平均（7.2±2.9）年。……